TAXOTERE
Drug
GENZYME CORPORATION
Total Payments
$2.3M
Transactions
609
Doctors
416
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $142,621 | 1 | 0 |
| 2020 | $59.74 | 4 | 4 |
| 2019 | $1.2M | 11 | 10 |
| 2018 | $9,645 | 234 | 199 |
| 2017 | $944,003 | 359 | 264 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 4 | 98.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,306 | 3 | 1.0% |
| Food and Beverage | $10,284 | 599 | 0.4% |
| Travel and Lodging | $3,594 | 3 | 0.2% |
Payments by Type
Research
$2.3M
4 transactions
General
$37,183
605 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase III Trial of Adjuvant TC vs TAC in Early Stage HER2-Negative Breast Cancer | GENZYME CORPORATION | $2.0M | 0 |
| Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial | GENZYME CORPORATION | $142,621 | 0 |
| A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT VS AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer | GENZYME CORPORATION | $135,000 | 0 |
Top Doctors Receiving Payments for TAXOTERE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Parks Adams | — | North Manchester, IN | $2.3M | 5 |
| , M.D | Medical Oncology | Boston, MA | $21,067 | 5 |
| , MD | Hematology | Brandon, FL | $2,977 | 2 |
| , MD | Medical Oncology | Cape Coral, FL | $2,965 | 1 |
| , MD | Urology | Arlington, TX | $143.56 | 7 |
| , DO | Hematology & Oncology | Arlington, TX | $126.32 | 6 |
| , M.D | Hematology & Oncology | Arlington, TX | $122.70 | 5 |
| , MD | Diagnostic Radiology | Arlington, TX | $120.62 | 5 |
| , M.D | Student in an Organized Health Care Education/Training Program | Portland, OR | $118.45 | 1 |
| Ana Aparicio | Hematology & Oncology | Houston, TX | $118.45 | 1 |
| , M.D | Medical Oncology | New York, NY | $118.45 | 1 |
| , M.D | Medical Oncology | Durham, NC | $118.45 | 1 |
| , M.D | Hematology & Oncology | Indianapolis, IN | $105.35 | 6 |
| , MD | Hematology | Indianapolis, IN | $84.23 | 5 |
| , MD | Hematology & Oncology | Indianapolis, IN | $82.73 | 4 |
| , MD | Anesthesiology | Indianapolis, IN | $80.04 | 4 |
| , M.D | Hematology | Leesburg, FL | $79.86 | 5 |
| , MD | Hematology & Oncology | Carlsbad, NM | $78.96 | 4 |
| , M.D | Hematology & Oncology | Roswell, NM | $74.40 | 4 |
| , M.D | Urology | Indianapolis, IN | $67.44 | 4 |
| , M.D | Medical Oncology | Los Angeles, CA | $67.40 | 1 |
| , MD | Radiation Oncology | Arlington, TX | $65.63 | 3 |
| , M.D | Urology | Carmel, IN | $64.84 | 4 |
| , MD | Hematology & Oncology | Waterloo, IA | $64.68 | 4 |
| , MD | Medical Oncology | Southlake, TX | $63.24 | 5 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $2.3M
- SANOFI-AVENTIS U.S. LLC $26,997
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 416
- Transactions 609
About TAXOTERE
TAXOTERE is a drug associated with $2.3M in payments to 416 healthcare providers, recorded across 609 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2021. In 2021, $142,621 was paid across 1 transactions to 0 doctors.
The most common payment nature for TAXOTERE is "Unspecified" ($2.3M, 98.4% of total).
TAXOTERE is associated with 3 research studies, including "Phase III Trial of Adjuvant TC vs TAC in Early Stage HER2-Negative Breast Cancer" ($2.0M).